JPRN-UMIN000000869已完成2 期
A Phase II Study of Capecitabine plus Paclitaxel Combination Chemotherapy in Patients with Metastatic Breast Cancer - KBCSG 0609 XP PhaseII
KBCSG (Kinki Breast Cancer Study Group)0 个研究点目标入组 42 人开始时间: 2007年10月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Have Capecitabine before 2) Have Paclitaxel for metastatic lesion before 3) Hypersensitivity to drugs 4) active double cancer 5) severe complication 6) in pregnancy or lactation 7) Symptomatic brain metastasis
研究者
相似试验
已完成
2 期
A Phase II study of capecitabine plus cisplatin (plustrastuzumab) for previously untreated advanced gastric cancer.untreated advanced gastric cancerJPRN-UMIN000006458Ehime University45
已完成
2 期
A Phase II study of capecitabine plus cisplatin (plus trastuzumab) for previously untreated advanced gastric cancer.untreated advanced gastric cancerJPRN-UMIN000005998Department of Digestive surgery, Kawasaki Medical University53
已完成
不适用
Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-UMIN000005697Chiba University Hospital42
招募中
不适用
Phase II Study of Paclitaxel in Combination with Carboplatin in Patients With Stage IB-II Cervical Cancer.cervical cancerJPRN-UMIN000012400Department of Obstetrics and Gynecology, Osaka Medical College30
进行中（未招募）
不适用
A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer - NDAdvanced or metastatic head and neck cancerLevel: HLTClassification code 10024530EUCTR2006-003775-13-ITOSPEDALE ONCOLOGICO DI BARI43